ALX Oncology (NASDAQ:ALXO) Sees Strong Trading Volume

ALX Oncology Holdings Inc. (NASDAQ:ALXO) shares saw unusually-high trading volume on Thursday . Approximately 976,491 shares were traded during trading, an increase of 118% from the previous session’s volume of 447,795 shares.The stock last traded at $15.09 and had previously closed at $15.00.

Analyst Ratings Changes

ALXO has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. Stifel Nicolaus reissued a “hold” rating and set a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of ALX Oncology in a research report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.83.

ALX Oncology Price Performance

The company has a current ratio of 5.21, a quick ratio of 5.21 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $735.13 million, a P/E ratio of -3.80 and a beta of 1.30. The business’s fifty day moving average price is $13.89 and its 200-day moving average price is $13.30.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). As a group, sell-side analysts predict that ALX Oncology Holdings Inc. will post -2.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ALX Oncology news, insider Sophia Randolph sold 12,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the transaction, the insider now owns 330,349 shares in the company, valued at $5,265,763.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Sophia Randolph sold 12,000 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $15.94, for a total value of $191,280.00. Following the completion of the transaction, the insider now owns 330,349 shares of the company’s stock, valued at approximately $5,265,763.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jason Lettmann purchased 4,400 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the transaction, the chief executive officer now directly owns 171,620 shares of the company’s stock, valued at $1,941,022.20. The disclosure for this purchase can be found here. Insiders sold 102,000 shares of company stock valued at $1,442,680 over the last three months. Insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of ALXO. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ALX Oncology during the fourth quarter valued at $28,000. CANADA LIFE ASSURANCE Co bought a new position in ALX Oncology in the 1st quarter valued at approximately $27,000. EntryPoint Capital LLC purchased a new stake in ALX Oncology during the 1st quarter valued at $32,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of ALX Oncology by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock worth $107,000 after purchasing an additional 3,825 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of ALX Oncology by 57.1% in the third quarter. Barclays PLC now owns 26,964 shares of the company’s stock worth $129,000 after purchasing an additional 9,796 shares during the last quarter. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.